# In-situ RhoA editing via heparinylated LNP-microsphere system for rheumatoid arthritis treatment

**Authors:** Yingchun Zhu, Lei Wang, Yingying Wei, Guanrong Li, Zheyuan Shi, Dianqing Wang, Qiang Wang, Liheng Wang, Weibing Si, Xing Yang

PMC · DOI: 10.1186/s12951-026-04040-x · Journal of Nanobiotechnology · 2026-01-23

## TL;DR

A new method for editing RhoA in macrophages using a heparinylated LNP-microsphere system shows promise for treating rheumatoid arthritis by reducing inflammation and joint damage.

## Contribution

A novel heparinylated LNP-microsphere system for in situ RhoA editing in synovial macrophages is developed and validated for rheumatoid arthritis treatment.

## Key findings

- Heparinylated LNPs improved mRNA/sgRNA transfection efficiency in macrophages.
- RhoA editing suppressed inflammation-related pathways and reduced joint inflammation in RA mouse models.
- The system enhanced LNP stability and retention for effective intra-articular delivery.

## Abstract

Macrophages play a pivotal role in modulating inflammation and osteoclastogenesis during the progression of rheumatoid arthritis (RA). Although local mRNA-mediated gene editing offers high precision and efficiency, there remains a lack of robust strategies tailored for effective editing of synovial macrophages. Here, we identified RhoA as a macrophage target via bioinformatics, validated its therapeutic potential, and built a heparinylated LNP-microsphere system (hLNP-RhoA−/−@MS) to replace PEGylated LNPs for in situ RhoA editing. Specifically, a low-molecular weight heparin-cholesterol conjugate was employed in place of PEG during LNP formulation. Substituting PEG with heparin on the LNP surface markedly enhanced the transfection efficiency of delivered mRNA/sgRNA. In parallel, integration of the microsphere system substantially improved LNP stability and intra-articular retention. In vitro RNA-seq analysis revealed broad and significant suppression of multiple key inflammation-related signaling pathways following RhoA editing. In the RA mouse model in vivo, hLNP-RhoA−/−@MS conferred pronounced therapeutic benefits, including attenuation of joint inflammation, inhibition of cartilage and bone destruction, and remodeling of the immune microenvironment, thereby demonstrating strong anti-RA efficacy. Overall, we present a feasible, effective local mRNA editing strategy for precise modulation of synovial macrophages in RA.

The online version contains supplementary material available at 10.1186/s12951-026-04040-x.

## Linked entities

- **Genes:** RHOA (ras homolog family member A) [NCBI Gene 387]
- **Diseases:** rheumatoid arthritis (MONDO:0008383)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** RHOA (ras homolog family member A) [NCBI Gene 387] {aka ARH12, ARHA, EDFAOB, RHO12, RHOH12}
- **Diseases:** rheumatoid arthritis (MESH:D001172)
- **Chemicals:** LNP (-)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12911233/full.md

## Figures

11 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12911233/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC12911233/full.md

---
Source: https://tomesphere.com/paper/PMC12911233